Streetbeat News

Regulatory

ENVB

Enveric Biosciences (ENVB) received a Notice of Allowance from the USPTO for a patent application involving its EVM201 Series, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:36 pm

UTRS

Minerva Surgical's stock is trading higher after being granted U.S. patent #11653972 for Medical Systems And Methods (For Resecting And Extracting Tissue).

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:33 pm

UCAR

U Power Limited (NASDAQ:UCAR), a Chinese EV battery power solution provider, received a notice of non-compliance from Nasdaq for not timely filing its annual report on Form 20-F for the year ended December 31, 2022. The company has 60 days to submit a plan to regain compliance.

Portfolio Pulse from Happy Mohamed

May 24, 2023 | 12:22 pm

SRPT

Sarepta Therapeutics shares are trading lower following an update on the regulatory review of SRP-9001, the company's gene therapy candidate.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:18 pm

ALIM

Alimera Sciences has completed enrollment for its NEW DAY clinical trial, a study designed to generate data for ILUVIEN, a baseline therapy for patients diagnosed with diabetic macular edema (DME).

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:17 pm

SRPT

Sarepta Therapeutics has updated the regulatory review of SRP-9001, with a new action date of June 22, 2023. The FDA is considering granting accelerated approval for SRP-9001 for Duchenne patients aged 4-5 years old, subject to the completion of the BLA review.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:05 pm

FDMT

4D Molecular Therapeutics (4DMT) will present interim data from its 4D-710 Phase 1/2 AEROW clinical trial for cystic fibrosis lung disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting on June 8.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:03 pm

ELOX

Eloxx Pharmaceuticals plans to advance its drug candidate ELX-02 into a pivotal trial for the treatment of Alport Syndrome with nonsense mutations after achieving remission in a patient during a Phase 2 study.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 12:02 pm

SPY

White House and GOP negotiators are set to resume debt talks this morning, according to Bloomberg. This could potentially impact the stock market and ETFs like SPY.

Portfolio Pulse from Benzinga Newsdesk

May 24, 2023 | 11:54 am